| Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial C Thieblemont, T Phillips, H Ghesquieres, CY Cheah, MR Clausen, ... Journal of Clinical Oncology 41 (12), 2238-2247, 2023 | 223 | 2023 |
| Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase … J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ... The Lancet Oncology 22 (4), 512-524, 2021 | 176 | 2021 |
| A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma F Morschhauser, P Feugier, IW Flinn, R Gasiorowski, R Greil, Á Illés, ... Blood, The Journal of the American Society of Hematology 137 (5), 600-609, 2021 | 116 | 2021 |
| Antibody therapy for acute myeloid leukaemia RE Gasiorowski, GJ Clark, K Bradstock, DNJ Hart British journal of haematology 164 (4), 481-495, 2014 | 70 | 2014 |
| Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic P Di Ciaccio, G McCaughan, J Trotman, PJ Ho, CY Cheah, ... Internal Medicine Journal 50 (6), 667-679, 2020 | 47 | 2020 |
| Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma … F Morschhauser, P Feugier, IW Flinn, RE Gasiorowski, R Greil, Á Illés, ... Blood 132, 782, 2018 | 46 | 2018 |
| KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). J Kuruvilla, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ... Journal of Clinical Oncology 38 (15_suppl), 8005-8005, 2020 | 39 | 2020 |
| CD300 molecule regulation of human dendritic cell functions RE Gasiorowski, X Ju, DNJ Hart, GJ Clark Immunology letters 149 (1-2), 93-100, 2013 | 33 | 2013 |
| Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the … JC Wight, M Yue, C Keane, A Johnston, K Linton, C Chin, SH Wai, ... British journal of haematology 187 (2), 174-184, 2019 | 31 | 2019 |
| A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission JL Hsu, CE Bryant, MS Papadimitrious, B Kong, RE Gasiorowski, ... Oncoimmunology 7 (4), e1419114, 2018 | 31 | 2018 |
| Effect of plasma and blood donations on levels of perfluoroalkyl and polyfluoroalkyl substances in firefighters in Australia: A randomized clinical trial R Gasiorowski, MK Forbes, G Silver, Y Krastev, B Hamdorf, B Lewis, ... JAMA network open 5 (4), e226257-e226257, 2022 | 25 | 2022 |
| Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol J Hocking, AP Schwarer, R Gasiorowski, S Patil, S Avery, J Gibson, ... Leukemia & lymphoma 55 (12), 2801-2807, 2014 | 20 | 2014 |
| New insights into the phenotype of human dendritic cell populations GJ Clark, F Kupresanin, PD Fromm, X Ju, L Muusers, PA Silveira, ... Clinical & translational immunology 5 (1), e61, 2016 | 17 | 2016 |
| Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma J Wong, E Gruber, B Maher, M Waltham, Z Sabouri-Thompson, I Jong, ... Leukemia 36 (6), 1654-1665, 2022 | 14 | 2022 |
| Is hematopoietic stem cell transplantation required to unleash the full potential of immunotherapy in acute myeloid leukemia? E Abadir, RE Gasiorowski, PA Silveira, S Larsen, GJ Clark Journal of Clinical Medicine 9 (2), 554, 2020 | 12 | 2020 |
| Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma PL Zinzani, R Ramchandren, A Santoro, E Paszkiewicz-Kozik, ... Blood Advances 6 (2), 590-599, 2022 | 11 | 2022 |
| Epcoritamab Monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with Relapsed/Refractory (R … T Phillips, C Thieblemont, H Ghesquieres, CY Cheah, MR Clausen, ... Blood 140 (Supplement 1), 9443-9445, 2022 | 10 | 2022 |
| Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia J Othman, E Verner, CS Tam, J Huang, L Lin, J Hilger, J Trotman, ... haematologica 103 (5), e223, 2018 | 10 | 2018 |
| Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia E Abadir, PA Silveira, RE Gasiorowski, M Ramesh, A Romano, ... Blood Advances 4 (7), 1206-1216, 2020 | 9 | 2020 |
| Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma … Y Karimi, H Ghesquieres, W Jurczak, C Cheah, M Clausen, P Lugtenburg, ... Journal of Clinical Oncology 41 (16_suppl), 7525-7525, 2023 | 8 | 2023 |
